A forum for researchers, students and applicants in the field of cyclodextrin technology
Cholesterol crystals (CCs), originally accumulating in the lysosome of cholesterol-laden cells, can aggravate the progression of atherosclerosis. β-cyclodextrin (CD) is
Most of the current non-pharmacological treatment strategies for atherosclerosis (AS) suffer from poor penetration into the plaque and only aim
Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been
A novel class of specifically engineered, dimerized cyclodextrin nanostructures was developed for the encapsulation of toxic biomolecules such as 7-ketocholesterol
SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed
A Chinese group has recently published [1] their interesting findings: in atherosclerosis β-CD (probaly methyl beta-cyclodextrin, but not specified) was
Although CD has been engineered into various nano-sized formulations, their main role was to incorporate a drug of interest for
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in
